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CLINICAL CHALLENGE
Diabetes
Question:
I read in the British Medical Journal that the UK
Prospective Diabetes Study Group recently announced the
results of their extensive long term studies on type 2
diabetics. What were their main f indings? Are there
implications for primary care doctors?
Comments:
The Uni ted K ingdom Prospective Diabetes Study
( U K P D S ) was a randomised c o n t r o l l e d t r i a l w h i c h
compared the effects of in tensive glucose control wi th
c o n v e n t i o n a l t r e a t m e n t on the r i sk of micro- and
macrovascular complicat ions of type 2 diabetes. As
hypertension was recognized to be an equally important
risk factor, the effects of t ight blood pressure control was
also examined in the study. The UKPDS started in 1977
and went on for 20 years and the main f ind ings were
published in four papers in September 1998.1-4
The part icipants of the UKPDS were 3867 newly
diagnosed patients with type 2 diabetes who, after three
months of dietary t reatment , had fas t ing glucose of
6 .1-15 mmol/1. They were randomly assigned to an
intensive policy with either a sulphonylurea or insulin, or
to a conventional policy with diet. During the tr ial , a
stepwise addition of hypoglycaemic agents was required
in many patients in the intensive treatment group in order
to ma in ta in fast ing glucose <6.0mmol/l. The dietary
policy also allowed patients to be given hypoglycaemic
agents when the i r g lycaemic goal ( f a s t i ng p lasma
glucose <15 mmol/1) was not met. The failure of diet and
the gradual fa i lures of the hypoglycaemic agents to
m a i n t a i n g lycaemic goals resu l ted in s u b s t a n t i a l
therapeutic overlap between comparison groups which
made subsequent comparisons of the different types of
therapy more difficult. In the blood pressure study, 1148
h y p e r t e n s i v e p a t i e n t s w i t h type 2 d iabe tes were
randomised to either tight blood pressure control (target
BP<150/85 mmHg wi th the use of an angio tens in
converting enzyme inhibitor or a beta blocker) or to less
tight control (BP< 180/105 mmHg). For both the diabetes
and hypertension management protocols, the primary
outcomes were "hard" c l in ica l end points , inc lud ing
severe cardiovascular events, vision loss and renal failure.
During the trial, HbA,c was reduced by 11% (from
7.9 to 7.0) in the intensive treatment group compared to
conventional treatment. The reduction was smaller than
that in DCCT where a reduction of 20% was achieved.5
An increased inc idence of hypoglycaemia and more
weight gain were observed in the in tens ive treatment
group but in t ens ive t r ea tmen t was associated wi th a
significant reduction of 12% in the risk for any diabetes
related end points. The observed decrease, however, was
in fact mainly due to the 25% reduction in the risk of
microvascular events. There was no effect on diabetes-
related mor ta l i ty or all cause morta l i ty . The blood
glucose s tudy therefore shows that t igh t ly controlling
blood glucose concentration in type 2 diabetes reduces the
risks of microvascular complications but the evidence on
macrovascular complications is inconclusive. As for the
beneficial effects of the different types of treatment,
sulphonylureas and insulin seem to produce equally good
results. The data on metformin is controversial. For
reasons that remain unclear, metformin was effective in
reducing impor tant end points in obese pat ients but
appeared to work less well in combination with other
drugs.
The blood pressure study showed that tight blood
pressure control in hypertensive patients with type 2
diabetes resulted in a s ignif icant reduction in both
diabetes related end points and diabetes related deaths.
Not only was there a significant reduction in the risk of
microvascular end points, there was also a 44% decrease
in the risk of stroke. Both angiotensin converting enzyme
inh ib i to r and beta blocker appeared to be s imilar ly
e f f ec t i ve in r e d u c i n g the i n c i d e n c e of d iabe t i c
complications. The study also highlighted the fact that
additional antihypertensive agents were often required and
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about one-third of the patients in the tight blood pressure
control group required three or more antihypertensive
agents to maintain blood pressure below the target levels.
In summary, tight glucose and blood pressure control
in patients with type 2 diabetes is important as it can
s i g n i f i c a n t l y reduce the r i sk of the long term
complications of diabetes. Based on the findings of the
UKPDS, it has been suggested that glycaemic goal should
be aimed at HbA ) C 7% or lower, taking into account the
condition of the patients, and any reduction of HbA t c
from a high va lue is impor t an t . In pat ients wi th
hypertension, the suggested goal of blood pressure is
around 140/85 mmHg or lower. •
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